Introduction
============

Each year, globally, around 150 million people struggle to meet the costs of accessing and using health care and approximately 100 million people are driven below the poverty line by such costs.[@R1] Many people delay or avoid health care because it is -- or, at least, is perceived to be -- unaffordable.[@R2]^--^[@R4] Most of those who struggle to meet the out-of-pocket costs of health care live in low-income countries that have poorly funded health systems and inadequate measures to ensure the financial protection of households against high health-care expenditure. However, the problem is not limited to such countries. In 2007, for example, 62% of the personal bankruptcies recorded in the United States of America (USA) were attributed to medical debt[@R5] and 11% of the individuals found insolvent in Australia cited ill-health or lack of health insurance as the primary reason for their insolvency.[@R6] Substantial and unpredictable one-off health-care payments and a steady flow of unbudgeted medical bills can lead many households -- particularly those already marginalized by socioeconomic disadvantage -- towards catastrophic health-care expenditure.[@R7]

The economic burden of illness in a household is only partly explained by out-of-pocket expenditure. The full evaluation of such burden requires a multidimensional framework -- to move beyond absolute spending to incorporate measures that examine the broader impacts of illness or injury on the household economy -- e.g. loss of employment -- as well as the affordability of care, a household's response to an injury or illness and the consequences of those responses for the household.[@R8]^,^[@R9] Most research in this area has been observational and has demonstrated that households will employ several strategies -- to deal with unbudgeted costs of medical care and unplanned departures from the workforce -- when coping with the onset of an illness or injury, especially in the main income earner. Such coping strategies include drawing on available social resources and networks, cutting back on essential living expenses, drawing on savings, selling assets, borrowing money, entering into formal or informal loan agreements, increasing credit or debt and even moving house.[@R3]^,^[@R4] Although these strategies may help leverage the resources needed to pay for care, they can also have adverse effects on treatment-seeking behaviour and the long-term economic well-being and resilience of the household.[@R3]^,^[@R4]^,^[@R7]

The provision of adequate financial protection -- from the costs of seeking and using medical care -- is a critical marker of the effectiveness of a health-care system.[@R10] The World Health Organization has encouraged its Member States to provide universal health coverage in some form and the United Nations has recently passed a declaration that calls for universal access to health care that does not cause financial hardship.[@R11] Such a goal -- like other post-2015 development goals aimed at alleviating poverty -- is unlikely to be achieved without further development and implementation of national health-insurance schemes. There is considerable evidence, most notably from the RAND Health Insurance Experiments,[@R12] that indicates how health insurance can protect the finances of households affected by illness or injury, by restricting individual health-care expenditure. However, although such insurance is one of the most important population-based policy interventions to mitigate the economic burden of injury or illness, it is not sufficient, on its own, to provide full protection from catastrophic health expenditure.[@R13]^,^[@R14] The effectiveness of health insurance in protecting individuals who are intense users of medical care -- e.g. those with chronic illness or long-term injuries -- has yet to be elucidated. Furthermore, limited coverage of services and high levels of co-payment can often mean that households with health insurance remain at risk of catastrophic health-care expenditures and economic hardship.[@R14]^,^[@R15]

Evidence of the effectiveness of simple education and support interventions, in both clinic- and community-based settings, has highlighted the potential value of more targeted and patient-focused strategies in reducing the household economic burden of illness. Interventions that help patients and caregivers to navigate through health and social-welfare support systems[@R16]^,^[@R17] and informal loan and microcredit schemes[@R18]^--^[@R20] have the potential to buffer those with illness and injury against financial hardship. As the evidence of the effectiveness and cost--effectiveness of such interventions becomes more robust, opportunities for the development and scale-up of such interventions need to be explored.

There have been few systematic reviews of interventions to reduce the household economic burden of illness or injury. The reviews that have been conducted have tended to take a population-based approach -- e.g. they have examined the impact of health-insurance programmes on entire populations -- and have often been based on studies that involved retrospective comparisons of before and after data. Furthermore, they have focused either on specific types of interventions -- e.g. programmes for the management of chronic illness[@R21] or health-insurance schemes[@R22]^--^[@R24] -- or have focused, narrowly, on out-of-pocket payments, as the sole measure of the economic impact of illness.[@R24] We decided to conduct a systematic review to try to determine the nature, scope and effectiveness of all interventions that have been designed to reduce the household economic burden of illness or injury.

Methods
=======

We searched electronic databases, using a predefined search strategy and confining the search to reports published on or before 31 January 2014 ([Box 1](#B1){ref-type="boxed-text"}). The reference lists of retrieved articles were screened to identify additional studies, and investigators known to be carrying out relevant research were contacted for unpublished data. Non-English articles were translated where necessary.

###### Basic literature search strategy for systematic review of interventions to reduce the household economic burden of ill health

The following databases were searched: CENTRAL, CINAHL, Econlit, Embase, MEDLINE, PreMEDLINE and PsycINFO

Search terms:

1\. "intervention" OR "program" OR "programme" OR "policy" OR "scheme"

2\. "catastrophic" AND "finance OR cost OR medical OR expenditure"

3\. "finance OR economic" AND "hardship OR strain OR stress OR well-being"

4\. "burden" AND "household financial OR household economic"

5\. "household" AND "economic impact"

6\. "out-of-pocket" AND "cost OR expenditure OR spend OR payment OR catastrophic"

A detailed search strategy for each database is available from the authors.

To be included in our review, a study (i) had to be a prospective controlled trial of one or more interventions -- i.e. a randomized or nonrandomized controlled trial, an interrupted time series study with control, or a controlled before-and-after study; (ii) involve a study population with any, chronic or acute, communicable or noncommunicable disease or injury; and (iii) use a study outcome that was a measure of the household economic burden of illness or injury -- e.g. out-of-pocket expenditure or level of economic hardship.

Interventions directed at the individual, household or population and delivered in any setting were eligible for inclusion. Studies that were primarily treatment or medical interventions -- e.g. cataract surgery or chemotherapy -- were excluded even if they included economic measures as additional outcomes.

Two authors carried out the literature search and screened titles and abstracts using a standardized eligibility assessment form based on our inclusion criteria. The full texts of articles of potential interest were reviewed by two authors and a final decision on which studies to include was confirmed by consensus. A third author provided arbitration if consensus was not reached. One author used a predefined form[@R25]^,^[@R26] to extract data from each included study. The data extraction was verified by a second author. Authors of included studies were contacted for any missing information or data. Where possible, effect estimates were calculated as standardized mean differences between the intervention and control groups, with 95% confidence intervals.[@R27] Where reported, data on the impact of the interventions on health-service-utilization -- e.g. numbers of hospital admissions or medical appointments -- and medication adherence were also collected.

The risk of bias in each of the included studies was assessed by one author --using the criteria suggested for Effective Practice and Organisation of Care reviews[@R28] -- and verified by a second author.

Quantitative analysis of the data was deemed inappropriate because of the heterogeneity in the collected data, designs and settings of the included studies.

Results
=======

The initial literature search identified 4330 citations. There were 90 articles of potential interest and, after examination of the full texts, nine articles described studies that met all of our inclusion criteria ([Fig. 1](#F1){ref-type="fig"}). Each of the nine articles -- seven conducted in the USA,[@R29]^--^[@R35] one in Finland[@R36] and one in China[@R37] -- described a single study. Most of the included studies had investigated adult urban patients with noncommunicable disease (6/9) and had involved data from more than 1000 participants (7/9; [Table 1](#T1){ref-type="table"}). Illness and injury inclusion criteria had been assessed using diagnostic codes, the health-service use reported in insurance claims, clinical presentations or self-reporting.
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###### Characteristics of the included studies on interventions to reduce the household economic burden of ill health

  Study                             Country   Study design (sample size)   Study objective                                                                                             Study population                                                                     Intervention vs control                                                                                                                                                                    Outcomes measured
  --------------------------------- --------- ---------------------------- ----------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------
  Jing et al. (2013)[@R37]          China     CBA (*n* = 2998)             To evaluate the impact of the New Cooperative Medical Schemes' reimbursement policies for chronic disease   Rural households in which one or more members have self-reported chronic disease     Higher reimbursement for essential drugs -- e.g. 80% for diabetes and hypertension medications -- and outpatient care -- e.g. 25% or 40% -- for specified chronic diseases vs usual care   Catastrophic health expenditure
  Heikkinen et al. (2011)[@R36]     Finland   NRCT (*n* = 147)             To evaluate cost of care between two different modes of delivering patient education                        Ambulatory orthopaedic surgery patients                                              Website containing biophysiological, social and financial information plus email contact with nurse vs face-to-face education                                                              Out-of-pocket costs
  Barry et al. (2013)[@R29]         USA       CBA (*n* = 1 907 218)        To evaluate the impact of FEHBP parity policy on out-of-pocket costs                                        Individuals aged ≤ 21 years with MH/SUD                                              Parity of benefits for MH/SUD services vs usual care                                                                                                                                       Share of total costs spent on MH/SUD services and mean out-of-pocket costs for MH/SUD
  Busch et al. (2013)[@R30]         USA       CBA (*n* = 29 615)           To evaluate the impact of FEHBP parity policy on spending and intensity of service use                      Enrolees of FEHBP with bipolar disorder, major depression or adjustment disorder     Parity of benefits for MH/SUD services vs usual care                                                                                                                                       Out-of-pocket costs and health-service utilization
  Choudhry et al. (2011)[@R31]      USA       RCT (*n* = 5855)             To evaluate the effect of providing full prescription drug coverage                                         Individuals with a principal or secondary diagnosis of acute myocardial infarction   Full prescription drug coverage vs usual coverage                                                                                                                                          Medication adherence and health-care spending, including out-of-pocket costs
  Choudhry et al. (2012)[@R32]      USA       ITS (*n* = 52 631)           To evaluate the impact of reductions in drug co-payments                                                    Individuals with diabetes or vascular disease                                        Co-payment elimination for patients with diabetes and reduction for patients on clopidogrel vs usual coverage                                                                              Out-of pocket costs, medication use and health-service utilization
  Davidoff et al. (2005)[@R33]      USA       ITS (*n* = 3413)             To evaluate the effects of the expansion of the SCHIP                                                       Children with chronic health conditions                                              Expansion of eligibility for SCHIP vs usual care                                                                                                                                           Out-of-pocket spending and health-service use
  Goldman et al. (2006)[@R34]       USA       ITS (*n* = 320 000)          To evaluate the impact of parity in insurance benefits                                                      Enrolees of the FEHBP accessing MH/SUD services                                      Parity of benefits for MH/SUD services vs usual care                                                                                                                                       Rate of MH/SUD utilization, out-of-pocket costs and total spending
  Van Houtven et al. (2013)[@R35]   USA       RCT (*n* = 187)              To evaluate the effect of a multicomponent intervention for caregivers of older adults                      Caregivers of patients with Alzheimer or Parkinson diseases                          Multicomponent training over 24 weeks for caregivers via the ASSIST programme vs social phone contacts while on waiting list                                                               Out-of-pocket costs

ASSIST: Assistance, Support, and Self-health Initiated through Skill Training; CBA: controlled before-and-after study; FEHBP: Federal Employees Health Benefits Program; ITS: interrupted time series; MH/SUD: mental health and substance use disorders; NRCT: nonrandomized controlled trial; RCT: randomized controlled trial; SCHIP: State Children's Health Insurance Program: USA: United States of America.

Seven of our included studies had evaluated policy interventions that involved health-insurance schemes ([Table 2](#T2){ref-type="table"}). Of these, three had involved the reduction or elimination of co-payments for disease-specific medications or outpatient care.[@R31]^,^[@R32]^,^[@R37] Another three studies had evaluated the effectiveness of a similar intervention -- that offered parity in service coverage for mental health and substance use disorders -- in different subgroups.[@R29]^,^[@R30]^,^[@R34] One study had investigated the extension of coverage of an existing health-insurance scheme to a new patient population.[@R33]

###### Characteristics of interventions investigated in the included studies on interventions to reduce the household economic burden of ill health

  Study                             Intervention details                                                                            Setting                      Target population
  --------------------------------- ----------------------------------------------------------------------------------------------- ---------------------------- -------------------------------------
  Choudhry et al. (2011)[@R31]      Health-insurance policy -- elimination of co-payments for disease-specific drugs                Health-insurance programme   Enrolees
  Choudhry et al. (2012)[@R32]      Health-insurance policy -- reduction or elimination of co-payments for disease-specific drugs   Health-insurance programme   Enrolees
  Jing et al. (2013)[@R37]          Health-insurance policy -- higher reimbursement for outpatient ambulatory services and drugs    County population            Enrolees, rural
  Davidoff et al. (2005)[@R33]      Health-insurance policy -- extended insurance coverage                                          Health-insurance programme   Enrolees, children
  Goldman et al. (2006)[@R34]       Health-insurance policy -- parity of coverage for disease-specific services                     Health-insurance programme   Enrolees
  Barry et al. (2013)[@R29]         Health-insurance policy -- parity of coverage for disease-specific services                     Health-insurance programme   Enrolees, children
  Busch et al. (2013)[@R30]         Health-insurance policy -- parity of coverage for MH/SUD services                               Health-insurance programme   Enrolees
  Heikkinen et al. (2013)[@R36]     Delivery of information and support using a web-based platform                                  Health service               Clinic-based population
  Van Houtven et al. (2013)[@R35]   Delivery of information and support using telephone and in-person training                      Health service               Clinic-based population, caregivers

MH/SUD: mental health and substance use disorders.

The other two studies trialled different models of delivering patient-focused education and support -- e.g. by web- or telephone-based communication or in-person.[@R35]^,^[@R36]

Out-of-pocket expenditure had been the primary outcome in six of our included studies -- including one post-hoc analysis -- and a supplementary outcome in another two ([Table 1](#T1){ref-type="table"}). The researchers involved in most of the studies had ascertained out-of-pocket expenditures from databases of insurance claims. Household economic burden had also been measured in terms of the likelihood of a household paying any out-of-pocket costs for care, the prevalence of catastrophic health expenditure -- i.e. out-of-pocket costs that were greater than 40% of the maximum amount that a household could pay -- and the prevalence of cost-related delays in seeking care. None of the studies had evaluated the effectiveness of an intervention in reducing economic hardship.

Six of the studies had also investigated the effectiveness of an intervention on clinical and health-system outcomes, health-service use, adherence to pharmaceuticals, direct costs to private health insurers or the indirect costs to patients and household caregivers in terms of the time spent seeking health care.

There was a high or unclear risk of bias in the randomized and nonrandomized controlled trials and controlled before-and-after studies ([Fig. 2](#F2){ref-type="fig"}; available from: <http://www.who.int/bulletin/volumes/93/2/14-139287>). In these studies, inadequate allocation-sequence generation and concealment could have resulted in an overestimate of the effects of an intervention on the household economic burden -- particularly since absolute out-of-pocket expenditure was often the main outcome and such expenditure was self-reported in three studies.[@R35]^--^[@R37] Attrition bias due to incomplete reporting of outcome data -- which may also lead to overestimates of an intervention -- was potentially an issue in three studies.[@R35]^--^[@R37] There was also a high risk of reporting bias in two of the studies.[@R35]^,^[@R36]
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The data we reviewed from interrupted time series studies (3/9) had a generally low risk of bias ([Fig. 3](#F3){ref-type="fig"}; available from: <http://www.who.int/bulletin/volumes/93/2/14-139287>). However, in such studies, there is some risk that the intervention effect may not have occurred independently of other changes occurring over time and that the outcome observed may have been influenced by confounding factors. These two issues may have resulted in an overestimate of the effect of the intervention. Attrition bias may also be an issue in these studies since there is unclear bias introduced by the incomplete reporting of outcome data.
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The outcomes of the interventions investigated in all of our included studies are summarized in [Table 3](#T3){ref-type="table"}.

###### Effects of interventions on measures of household economic burden

  Type of measure and study                                          Source of data     Measure                                                                              Relative difference (95% CI)                                 *P*                      Reference period (months)   Out-of-pocket cost for control group, mean (SD)   Standardized mean difference (95% CI)^a^
  ------------------------------------------------------------------ ------------------ ------------------------------------------------------------------------------------ ------------------------------------------------------------ ------------------------ --------------------------- ------------------------------------------------- ------------------------------------------
  **Out-of-pocket costs**                                                                                                                                                                                                                                                                                                                        
  Choudhry et al. (2011)[@R31]                                       Insurance claims   Relative ratio of costs per patient                                                  Prescription drugs: 0.70 (0.65 to 0.75)                      \< 0.001                 12                          1164 (1331)                                       −0.30 (−0.35 to −0.25)
  Non-drug: 0.82 (0.72 to 0.94)                                      0.005              12                                                                                   618 (1480)                                                   −0.11 (−0.17 to −0.06)                                                                                 
  All: 0.74 (0.68 to 0.80)                                           \< 0.001           12                                                                                   1781 (2263)                                                  −0.26 (−0.31 to −0.20)                                                                                 
  Cardiovascular-specific, prescription drugs: 0.49 (0.46 to 0.53)   \< 0.001           12                                                                                   665 (721)                                                    −0.58 (−0.64 to −0.53)                                                                                 
  Cardiovascular-specific, non-drug: 0.91 (0.82 to 1.00)             0.05               12                                                                                   235 (349)                                                    −0.10 (−0.15 to −0.04)                                                                                 
  Cardiovascular-specific, total: 0.60 (0.56 to 0.64)                0.001              12                                                                                   900 (888)                                                    −0.50 (−0.55 to −0.45)                                                                                 
  Choudhry et al. (2012)[@R32]                                       Insurance claims   Relative ratio of costs per patient                                                  Statin, medication and insurance co-payments: 0.05 (NR)^b^   NR                       1                           11.95 (11.44)                                     −1.02 (−1.06 to −0.90)
  Statin, medical: 0.90 (0.83 to 0.98)^b^                            NR                 1                                                                                    NR                                                           --                                                                                                     
  Statin, pharmacy: 0.65 (0.62 to 0.68)^b^                           NR                 1                                                                                    NR                                                           --                                                                                                     
  Statin, total: 0.79 (0.75 to 0.83)^b^                              NR                 1                                                                                    NR                                                           --                                                                                                     
  Clopidogrel, medication and insurance co-payments: 0.61 (NR)^b^    NR                 1                                                                                    14.43 (13.38)                                                −0.43 (−0.50 to −0.35)                                                                                 
  Clopidogrel, medical: 0.76 (0.61 to 0.94)^b^                       NR                 1                                                                                    NR                                                           --                                                                                                     
  Clopidogrel, pharmacy: 0.72 (0.67 to 0.76)^b^                      NR                 1                                                                                    NR                                                           --                                                                                                     
  Clopidogrel, total: 0.74 (0.66 to 0.82)^b^                         NR                 1                                                                                    NR                                                           --                                                                                                     
  Davidoff et al. (2005)[@R33]                                       Self-report        Change in percentage of patients paying                                              At least US\$ 2000: −1.3 (−8.94 to 6.34)                     0.05                     12                          NR                                                --
  US\$ 500--1999: −4.0 (−14.39 to 6.39)                              \> 0.05            12                                                                                   NR                                                           --                                                                                                     
  US\$ 1--499: 3.2 (−7.19 to 13.59)                                  \> 0.05            12                                                                                   NR                                                           --                                                                                                     
  Nothing: 2.2 (−2.31 to 6.71)                                       \> 0.05            12                                                                                   NR                                                           --                                                                                                     
  Goldman et al. (2006)[@R34]                                        Insurance claims   Difference in difference change in mean costs per patient of MH/SUD services, US\$   National PPO: 4.48 (0.91 to 8.06)                            ≤ 0.05                   24                          NR                                                --
  Mid-Atlantic PPO 1: −15.43 (−26.14 to −4.73)                       ≤ 0.05             24                                                                                   NR                                                           --                                                                                                     
  Mid-Atlantic PPO 2: −13.82 (−23.96 to −3.67)                       ≤ 0.05             24                                                                                   NR                                                           --                                                                                                     
  Northeastern PPO 1: −8.78 (−21.14 to 3.57)                         \> 0.05            24                                                                                   NR                                                           --                                                                                                     
  Northeastern PPO 2: −48·12 (−66.85 to −29.39)                      ≤ 0.05             24                                                                                   NR                                                           --                                                                                                     
  Western PPO: −49.80 (−61.17 to −38.43)                             ≤ 0.05             24                                                                                   NR                                                           --                                                                                                     
  Southern PPO: −87.06 (−99.73 to −74.38)                            ≤ 0.05             24                                                                                   NR                                                           --                                                                                                     
  Barry et al. (2013)[@R29]                                          Insurance claims   Difference in difference change in mean costs per patient of MH/SUD services, US\$   −178 (−257 to −97)^c^                                        ≤ 0.05                   12                          NR                                                --
  Busch et al. (2013)[@R30]                                          Insurance claims   Difference in difference change in mean costs per patient, US\$                      Bipolar disorder: −148 (−217 to −85)                         NR                       12                          NR                                                --
  Major depression: −100 (−123 to −77)                               NR                 12                                                                                   NR                                                           --                                                                                                     
  Adjustment disorder: −68 (−84 to −54)                              NR                 12                                                                                   NR                                                           --                                                                                                     
  Heikkinen et al. (2011)[@R36]                                      Self-report        Relative ratio of costs per patient                                                  Total: 0.98 (NR)                                             NR                       NR                          240 (264)                                         −0.02 (−0.35 to 0.32)
  Hospital: 1.04 (NR)                                                NR                 NR                                                                                   124 (134)                                                    0.04 (−0.30 to 0.37)                                                                                   
  Laboratory tests and X-ray examinations: 0.45 (NR)                 NR                 NR                                                                                   216 (242)                                                    −0.64 (−1.29 to 0.01)                                                                                  
  Medication: 1.16 (NR)                                              NR                 NR                                                                                   26.2 (19.29)                                                 0.17 (−0.20 to 0.53)                                                                                   
  Physician fees: 0.95 (NR)                                          NR                 NR                                                                                   51.39 (64.24)                                                −0.05 (−0.58 to 0.48)                                                                                  
  Travel: 1.17 (NR)                                                  NR                 NR                                                                                   18.73 (24.79)                                                0.11 (−0.36 to 0.57)                                                                                   
  Equipment: 1.10 (NR)                                               NR                 NR                                                                                   11.63 (8.03)                                                 0.14 (−0.41 to 0.69)                                                                                   
  Medical certificate: 0.83 (NR)                                     NR                 NR                                                                                   8.02 (9.09)                                                  −0.15 (−0.64 to 0.34)                                                                                  
  Escort: 4.44 (NR)                                                  NR                 NR                                                                                   7.88 (9.19)                                                  0.94 (−0.45 to 2.32)                                                                                   
  Utility bills: 1.71 (NR)                                           NR                 NR                                                                                   2.49 (1.70)                                                  0.82 (−0.10 to 1.73)                                                                                   
  Parking: 1.27 (NR)                                                 NR                 NR                                                                                   1.49 (1.85)                                                  0.23 (−0.39 to 0.86)                                                                                   
  Additional: 0.29 (NR)                                              NR                 NR                                                                                   120 (144)                                                    −0.68 (−2.42 to 1.06)                                                                                  
  Van Houtven et al. (2013)[@R35]                                    Self-report        Logged costs per patient, US\$                                                       Caregiver: −54.32 (−143.81 to 35.17)^d^                      NR                       1                           NR                                                --
  Care-recipient: 192.25 (−361.86 to 746.36)^d^                      NR                 1                                                                                    NR                                                           --                                                                                                     
  Total: 57.42 (−461.39 to 576.23)^d^                                NR                 1                                                                                    NR                                                           --                                                                                                     
  **Households with catastrophic health expenditure**                                                                                                                                                                                                                                                                                            
  Jing et al. (2013)[@R37]                                           Self-report        Difference in difference change in proportion of households, %                       0.53 (NR)                                                    \> 0.05                  12                          −2.10 (5.75)                                      NR
  **Delaying the seeking of care because of costs**                                                                                                                                                                                                                                                                                              
  Davidoff et al. (2005)[@R33]                                       Self-report        Change in percentage of patients who delayed seeking care due to cost                −1.7 (−6.6 to 3.2)                                           NR                       12                          NR                                                --
  **Probability of out-of-pocket costs**                                                                                                                                                                                                                                                                                                         
  Van Houtven et al. (2013)[@R35]                                    Self-report        Probability that household paid                                                      Any caregiver costs: 0.26 (0.09 to 0.44)                     NR                       1                           NR                                                --
  Any care-recipient costs: 0.11 (−0.06 to 0.29)                     NR                 1                                                                                    NR                                                           --                                                                                                     
  Any costs: 0.23 (0.12 to 0.34)                                     NR                 1                                                                                    NR                                                           --                                                                                                     

CI: confidence interval; MH/SUD: mental health and substance use disorders; NR: not reported; PPO: preferred provider organization; SD: standard deviation; US\$: United States dollars.

^a^ The difference in mean effects in the intervention and control groups, divided by the pooled standard deviation.

^b^ Relative changes in out-of-pocket costs were adjusted for age, sex, income, race, coronary artery disease, congestive heart failure, diabetes, hypertension, Charlson comorbidity score, number of hospitalizations and prescription drugs on enrolment.

^c^ Difference in difference analysis of gender-, age- and area-adjusted change in annual out-of-pocket costs among those in at least the 90th percentile of MH/SUD treatment expenditure. The corresponding proportion of total MH/SUD costs fell significantly by 5% (*P* ≤ 0.05).

^d^ Confidence interval calculated from reported standard error.

Two studies conducted in the USA evaluated the effectiveness of reducing or eliminating co-payments and found statistically significant reductions in out-of-pocket costs for cardiovascular pharmaceuticals and medical services.[@R31]^,^[@R32] Another three studies conducted in the USA evaluated the effectiveness of parity in service coverage for mental health problems and substance use disorders.[@R29]^,^[@R30]^,^[@R34] In these three studies, statistically significant reductions in out-of-pocket expenditure were reported for the whole study population,[@R34] among children with high expenditure[@R29] and in specific disease groups.[@R30] For example, the reported mean annual reductions in out-of-pocket costs per patient were 148, United States dollars (US\$) for bipolar disease, US\$ 100 for major depression and US\$ 68 for adjustment disorder.[@R30] A sixth study in the USA found a statistically significant association between the expansion of health-insurance coverage and the proportion of people who had moderate out-of-pocket costs of US\$ 1--2000 per person.[@R33]

In rural China, the implementation of a voluntary community-based insurance programme that offered higher reimbursement for outpatient services for a poor population was not found to reduce the prevalence of catastrophic health expenditure significantly.[@R37]

In Finland, the web-based delivery of information to patients was not associated with any change in out-of-pocket expenditure.[@R36] In the USA, an intervention that targeted information at caregivers was found to increase the care-associated spending of the caregivers and had no significant effect on total out-of-pocket expenditure on health for the patients.[@R35]

Outcomes other than out-of-pocket expenditure were assessed in several studies ([Table 4](#T4){ref-type="table"}; available from: <http://www.who.int/bulletin/volumes/93/2/14-139287>). Two insurance interventions were adequately powered to measure their effect on clinical and health-service outcomes. One study found significant reductions in the rates of total major vascular events or revascularization.[@R31]^,^[@R32] None of the other seven studies we included in our systematic review appeared to show a significant impact on the clinical or health-service outcomes assessed -- probably because they were underpowered to assess the effect.

###### Other patient outcomes assessed in the included studies

  Patient outcome                                                      Choudhry et al. (2011)[@R31]   Choudhry et al. (2012)[@R32]   Davidoff et al. (2005)[@R33]   Goldman et al. (2006)[@R34]   Jing et al. (2013)[@R37]   Barry et al. (2013)[@R29]   Busch et al. (2013)[@R30]   Heikkinen et al. (2011)[@R36]   Van Houtven et al. (2013)[@R35]
  -------------------------------------------------------------------- ------------------------------ ------------------------------ ------------------------------ ----------------------------- -------------------------- --------------------------- --------------------------- ------------------------------- ---------------------------------
  **Clinical**                                                                                                                                                                                                                                                                                                       
  Readmission for major vascular event or coronary revascularization   Yes                            No                             No                             No                            No                         No                          No                          No                              No
  Rate of total major vascular events or revascularization             Yes                            Yes                            No                             No                            No                         No                          No                          No                              No
  **Health-system feature**                                                                                                                                                                                                                                                                                          
  Private health-insurance coverage                                    No                             No                             Yes                            No                            No                         No                          No                          No                              No
  **Health-service use and access**                                                                                                                                                                                                                                                                                  
  Emergency presentations                                              No                             Yes                            No                             Yes                           No                         No                          No                          No                              No
  Hospital admissions                                                  No                             Yes                            No                             Yes                           No                         No                          Yes                         Yes                             No
  Physician visits                                                     No                             Yes                            No                             Yes                           No                         No                          Yes                         Yes                             No
  Other^a^                                                             No                             No                             No                             No                            No                         No                          No                          Yes                             No
  Unmet needs^b^                                                       No                             No                             No                             Yes                           No                         No                          No                          No                              No
  **Adherence**                                                                                                                                                                                                                                                                                                      
  Medication possession ratio^c^                                       Yes                            No                             No                             No                            No                         No                          No                          No                              No
  Full adherence                                                       Yes                            No                             No                             No                            No                         No                          No                          No                              No
  Medication filling                                                   No                             Yes                            No                             No                            No                         No                          No                          No                              No
  **Direct and indirect costs**                                                                                                                                                                                                                                                                                      
  Costs to private health insurer                                      Yes                            Yes                            No                             No                            No                         No                          No                          No                              No
  Time costs^d^                                                        No                             No                             No                             No                            No                         No                          No                          Yes                             No

^a^ First aid, nurses and other health-care professionals.

^b^ Medical, dental, prescription drugs and mental health services.

^c^ The number of days a patient had a supply of each medication class available divided by the number of days the patient was eligible for that medication.

^d^ Including work and free time spent attending laboratory tests, X-ray examinations and receiving patient-targeted education and time spent off work, on sick leave.

Discussion
==========

To the authors' knowledge this is the only systematic review to synthesize published evidence on the effectiveness of interventions that address the diverse ways that illness and injury adversely affect household economics. In the reviewed studies, the economic burden of illness at household level was measured predominantly in terms of out-of-pocket costs. The interventions that were found to be most effective at mitigating the burden of illness were implemented in the context of existing health-insurance schemes and involved reducing or eliminating co-payments for disease-specific treatments. Offering parity in the benefits for specific illnesses also significantly reduced out-of-pocket costs.

However, any reductions in out-of-pocket expenditure should be interpreted in the context of total spending -- by the individual and the household -- for the management of an illness or injury.[@R30] One study reported that, although the 21% reduction in out-of-pocket expenditure found in their study was statistically significant, the absolute annual reduction -- of US\$ 100--148 per patient -- was unlikely to confer protection from catastrophic expenditure.[@R30] Total household expenditure on health-related care -- including the costs of transport, home assistance, medical equipment and accommodation -- can be much greater than the direct out-of-pocket costs of medicines and surgery.[@R38] Moreover, such indirect costs of care are seldom covered by health-insurance schemes, particularly in low-income settings. Few of our included studies incorporated other categories of out-of-pocket expenditure beyond the direct costs of medical care. Interventions that solely reduce co-payments for specific aspects of care will only be effective if the care that is covered represents the main economic burden of the illness or injury at household level. Furthermore, many households may have more than one member with illness or injury. Therefore, interventions will need to move beyond targeting disease-specific aspects of treatment and, instead, take a holistic view of the multiple and diverse ways that illness and injury affect household economic circumstances.

Of the nine studies we reviewed, seven involved changes to -- or extensions of -- an existing package of health-insurance benefits, with the sole aim of shifting the costs of care to the insurer and minimizing the costs to the patient. Only one of these health-insurance studies was conducted in a low- or middle-income country. Although most of the health-insurance interventions were associated with statistically significant effects within the study period, such interventions will not be put into widespread practice unless they can be shown to be economically viable. To the authors' knowledge, only one of the health-insurance studies was accompanied by a published cost--effectiveness investigation of the type needed to inform priority setting and resource planning for any sustainable intervention. In low- and middle-income countries, the financial sustainability of such measures is critical. If the post-2015 development goals relating to poverty reduction are to be achieved, good evidence is needed to inform the development of stronger and more financially sustainable health systems in these settings.

There is a general scarcity of evaluations of innovative interventions to address the economic burden of illness and injury. Such interventions have the potential to supplement existing health-insurance policies, particularly those being rolled out to achieve universal health coverage in low- and middle-income settings. The interventions uncovered in this review tended to be health-insurance-based or, to a lesser extent, involve some form of patient education. If used in isolation, such interventions cannot resolve the fundamental issues of social disadvantage and poverty and overlook the multidimensional pathways in which illnesses or injuries are linked to economic outcomes. For instance, there appear to have been few attempts to examine the role of strategies such as income support or programmes to support household consumption in addressing the financial challenges of long-term chronic illness. This might be due to the narrow disciplinary perspectives of the relevant researchers.[@R39]

This review highlights a need for method development in this field, to take account of the capacity of households to afford out-of-pocket expenditure and the impact of coping strategies on household economic outcomes. There is an interconnection and, potentially, a vicious cycle between poor economic circumstances and illness.[@R3]^,^[@R40] Social disadvantages can predispose individuals to a risk of illness. This, in turn, can predispose individuals and their households to illness-related poverty and economic hardship. These economic consequences can further perpetuate poor health, through impaired quality of life, depression and non-adherence to treatment. Interventions to address the economic burden of illness have the potential to break this nexus. However, research has been slow to adopt tools for measuring outcomes in this field beyond out-of-pocket expenditure, and the relevant studies that have been conducted have been of variable quality and rarely randomized controlled trials. There have also been inconsistencies in the measurement and reporting of outcomes such as out-of-pocket costs and catastrophic health expenditures.[@R41]^,^[@R42] Once a consistent approach to measuring outcomes has been developed, research in this area will allow for greater comparability between studies[@R8]^,^[@R9] and offer opportunities for the routine assessment of household expenditures within research on clinical interventions.[@R43]^,^[@R44]

This review has limitations. First, the authors of excluded studies were not contacted to determine if they had collected data on relevant outcomes but not reported them. Second, the household economic burden of illness or injury was not the primary outcome in all of the included studies. It is possible that some included studies were not sufficiently powered to detect a change in this outcome. Third, this review was limited to studies published in the peer-reviewed literature. Fourth, most of the included studies were conducted in the USA and so low- and middle-income settings were underrepresented. Finally, there were few randomized controlled trials included. As a result of the two latter issues, our findings are unlikely to be representative of all health systems.

Conclusion
==========

Health-insurance programmes that reduce or eliminate co-payments for defined illness-specific treatments can effectively provide some financial protection, by reducing out-of-pocket expenditure. However, little is known about the cost--effectiveness of such programmes and about other forms of intervention that may provide relief from adverse economic outcomes to households. Given the multiple and diverse ways that illness and injury can affect the economic circumstances of households, this review highlights the need for method development in this field -- above and beyond the limited focus on out-of-pocket expenditure. Additionally, especially in low- and middle-income countries, there is wide scope for research on the effectiveness of innovative non-insurance interventions that could provide low-cost and better-targeted support.
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